Project Grant R37CA292781
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$623K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is providing $402,401.00 to Emory University to develop a PET CCR2 imaging agent to profile the pancreatic ductal adenocarcinoma (PDAC) microenvironment. The project will run from July 4, 2024 to June 30, 2026. The goal is to advance the understanding of PDAC, a highly aggressive form of cancer that is the 4th leading cause of cancer-related death....
This $263,086 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of a multiparametric endoscopic ultrasound (MPEUS) imaging system to improve pancreatic cancer screening and characterization. The key products and services to be delivered include: Developing a real-time MPEUS system that integrates B-mode imaging, ultrasensitive microvessel imaging, shear-wave elastography, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding for research at the University of Texas MD Anderson Cancer Center focused on understanding the role of sulfatide metabolism in the development and progression of precursor lesions for pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this $616,495 award, which runs from March 1, 2025 to February 28, 2030, include: Defining the...
This federal Project Grant award of $653,452 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to evaluate the impact of a CD73 inhibitor in combination with neoadjuvant FOLFIRINOX chemotherapy and PD-1 inhibition in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). The goal is to comprehensively assess how CD73 inhibition affects tumor adenosine metabolism, signaling, and immunosuppression in the PDAC tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance a local controlled release platform for intratumoral delivery of hyaluronidase to target the dense extracellular stroma in pancreatic ductal adenocarcinomas (PDAC). The $599,474 award will fund a 5-year research project with the following key objectives: Use multi-scale modeling to define implant design parameters needed to achieve uniform hyaluronidase distribution within...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,849,821 to The Leland Stanford Junior University to develop a theragnostic radiopharmaceutical for the treatment of pancreatic cancer. The project aims to: 1) assess and optimize peptide ligands targeting the claudin-4 protein, which is overexpressed in pancreatic tumors; 2) evaluate copper-64 and gallium-68 labeled claudin-4 peptides for PET imaging in cell culture and mouse...
This Project Grant award of $1,769,090.00 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286) aims to develop an innovative photodynamic priming (PDP) approach to enhance the efficacy of chemoimmunotherapy for pancreatic ductal adenocarcinoma (PDA). The project will use optical molecular imaging to engineer a PD-L1 targeted liposome that...
The National Cancer Institute (NCI) awarded a $599,191 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of California, San Diego (UCSD) to develop and validate new perfusion measurement techniques using 3D Dynamic Contrast-Enhanced Ultrasound (3D DCE-US) imaging. The goal is to characterize complex tumor vascular properties and detect microvascular changes following cancer therapy, with the aim of improving non-invasive bedside diagnostics and treatment...
This $654,197 federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and utilize patient-derived xenograft (PDX) tumor models to study molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) and their response to standard-of-care and investigational therapies. The key objectives are to: 1) Define the molecular...
This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Southwestern Medical Center aims to determine whether inhibiting the protein pleiotrophin (PTN) is therapeutically effective in preclinical models of pancreatic ductal adenocarcinoma (PDA). PDA is a highly aggressive form of pancreatic cancer with a poor prognosis. The project seeks to build on the awardee's prior work demonstrating that blocking PTN can...